Nucleic acids encoding inactive variants of human telomerase
AssigneesGeron Corporation, The Regents of the University of Colorado
InventorGregg B. Morin
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. Catalytically inactive variants comprising deletions or other mutations are provided.
Claims9
An isolated nucleic acid that encodes a polypeptide having at least 90% sequence identity to SEQ ID NO:2 and wherein said polypeptide comprises one or more deletions selected from the group consisting of:
- a) all of amino acid residues 930-934;
- b) at least 10 consecutive amino acids from residues 637-660;
- c) at least 10 consecutive amino acids from residues 748-766;
- d) at least 10 consecutive amino acids from residues 1055-1071;
- and
- e) at least 10 consecutive amino acids from residues 1084-1116;
- wherein said polypeptide lacks processive telomerase enzyme activity
- and wherein said polypeptide inhibits telomerase catalytic activity when expressed in a cell expressing human telomerase reverse transcriptase (hTRT) and human telomerase RNA component.
An isolated nucleic acid that encodes a polypeptide having at least 90% sequence identity to SEQ ID NO:2 and wherein said polypeptide comprises one or more deletions selected from the group consisting of:
- a) all of amino acid residues 930-934;
- b) at least 10 consecutive amino acids from residues 637-660;
- c) at least 10 consecutive amino acids from residues 748-766;
- d) at least 10 consecutive amino acids from residues 1055-1071;
- and
- e) at least 10 consecutive amino acids from residues 1084-1116;
- wherein said polypeptide lacks processive telomerase enzyme activity
- and wherein said polypeptide:
- (a) binds a human telomerase RNA component;
- or
- (b) binds human telomeres.
Dependencies are inferred from the claim text.